CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 307 enrolled
Drug / intervention
Rebif®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01207648
NCT01207648N/ACompleted
CompareCT.gov

Retrospective Cohort Study of Rebif® Use in Pediatric MS Patients

EMD Serono·observational·Posted Sep 23, 2010·Updated May 15, 2015

In Brief

An observational study evaluating Rebif® for Multiple Sclerosis. Completed, enrolled 307 participants across 18 sites in 8 countries.

Detailed Summary

The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif® (subcutaneous interferon \[IFN\]-beta-1a) in children and adolescents, using information already recorded in medical records. The study duration is 13 July 2010 (first data collected) to 13 July 2011 (last data collected). In this study, Data of the subjects evaluated between 1997 and 2009 was observed.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesArgentina, Canada, France, Italy, Russia, Tunisia, United States, Venezuela
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2010
Enrollment StartJul 1, 2010
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.8 years ago

Interventions

Rebif®drug

This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)